Novartis India Ltd(NOVARTIND)

NSE: NOVARTINDBSE: 500672

₹ 1,786.45-2.63%refreshed 26 Oct, 03:00 pm ISTMarket cap: ₹ 4,411 crNext results: 3 Nov 2026Website: www.novartis.com/in-en/Updated: 24 Oct 2026

About

Novartis India Ltd is a branded pharmaceutical company selling prescription medicines across therapy areas including cardiology, pain management, women's health, CNS, transplant, and ophthalmology in India. In FY26 it reported revenue of ₹354 crore. On July 29, 2026, ChrysCapital Group acquired a 70.68% stake from Novartis AG, triggering a full commercial and operational reset including a planned name change within 120 days.^[1][2]

Ownership and strategic reset

ChrysCapital Group closed the purchase of a 70.68% stake from Novartis AG on July 29, 2026, making it the new promoter and triggering a full commercial reset with a new management team and board.^[2]
The company plans to change its name within 120 days of the ChrysCapital takeover, subject to relevant stakeholder approvals.^[2]
Under the prior partner-led outsourced distribution model, revenue was flat to declining at a -2% CAGR from FY23 to FY26 (₹379 crore to ₹354 crore), with no dedicated field force behind brands.^[2]

Therapy areas and strategy

New management has selected six anchor therapy areas - Cardiology, Pain Management, Women's Health, CNS, Transplant, and Ophthalmology - which collectively contribute 40 - 50% of incremental value added annually to the Indian pharma market.^[2]
Management has adopted an asset-light model, ruling out investment in manufacturing; capital is to be deployed in marketing, brand promotion, and M&A, with supply managed via contract manufacturing partners.^[2]

Key brands

Voveran (pain management) had MAT revenue of ~₹240 crore as of MAT July 2026.^[2]
Minipress XL (alpha-blocker, cardiology) had MAT revenue of ₹228 crore as of MAT July 2026, with a 6.5% revenue CAGR over MAT June 2022 - 2026, and holds ~63% value market share in the alpha-blocker CVM segment.^[2]

Distribution and field force

The company is building a 900+ member field force from scratch across therapy-aligned divisions, targeting coverage of ~150,000 HCPs pan-India, with full operational readiness expected by end of Q3 FY27 (December 2026).^[2]
Distribution is expanding from ~4 C&Fs to ~25 C&Fs with 4,000 - 5,000 distributors, to be completed within approximately 45 days of the Q1 FY27 call.^[2]

Key operating numbers

Minipress XL MAT revenue was ₹228 crore as of MAT July 2026, down -8% YoY.^[2]
The in-licensed ophthalmology portfolio (Accentrix and Pagenax from NHPL) had a total portfolio size of ~₹100 crore+ as of MAT July 2026.^[2]
Net cash on the balance sheet was ₹668 crore as of March 2026.^[2]
The Indian pharma market (IPM) grew at 9 - 10% in FY26.^[2]

Recent acquisitions and in-licensing

NIL acquired the rights to use the Minipress trademark from Pfizer Inc. for ₹1,250 crore, funded by a combination of internal accruals and debt, providing a platform entry into cardiology.^[2]
NIL signed an exclusive distribution and promotion agreement for NHPL's retina portfolio (ranibizumab and brolucizumab - Accentrix and Pagenax) for an upfront fee of ₹10 crore, entering the ophthalmology therapy area.^[2]

Expansion and growth targets

Management targets an annualised revenue run rate of ~₹650 crore for FY27, including recent acquisitions, and aspires to at least double revenues over 4 - 5 years from this base by FY31.^[2]
Incremental quarterly operating costs of ₹40 - 50 crore are expected from Q2 FY27 onward for field force and marketing build-out, versus a legacy quarterly cost run rate of ₹10 - 15 crore.^[2]
Future M&A will focus on bolt-on brands in the six anchor therapy areas, with a hurdle rate of ~12 - 12.5% and a payback period of 8 - 9 years.^[2]
Significant repayment of acquisition debt taken for Minipress is expected before end of FY27; capital-raising options are being explored.^[2]

Market Cap

₹4,411 Cr

High / Low

₹2,588 / 750

Stock P/E

46.3

Price / Book

5.5

Book Value

₹331

EPS

₹37.7

No. of Shares

2.47 Cr

ROCE

16.3%

ROE

11.6%

OPM

33.3%

Debt / Equity

0.00

Sales

₹354 Cr

Net Profit

₹93 Cr

Promoter holding

70.7%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials